Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

MENLO PARK, Calif., Nov. 14, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cysteine protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, presented data showing that one of the company's spectrum-selective cathepsin inhibitors demonstrated efficacy in a mouse model of bone cancer pain.  Virobay has a series of advanced, spectrum-selective cathepsin inhibitors with structural diversity and demonstrated activity in bone cancer and related pain.  VBY-825, a prototype compound within this series, is an orally bioavailable, highly potent, reversible inhibitor of a subset of cathepsin proteases (including cathepsins S, K, L and B) that demonstrated protection from bone destruction and remodeling in this metastatic breast cancer model, as well as significant analgesic activity.  These preclinical data suggest that Virobay's spectrum-selective cathepsin inhibitors have potential therapeutic utility in the treatment of metastatic and primary bone cancer and cancer-related bone pain, with a mechanism of action that would be highly complementary to standard chemotherapy.

The data were presented in a poster, titled "Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer," by Holsinger, et al., at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, on Sunday, November 13th.

"These preclinical data provide a compelling demonstration of the therapeutic potential of Virobay's cathepsin inhibitors in bone cancer and bone cancer pain," said Robert Booth, PhD, Virobay's president and chief executive officer.  "The data demonstrate that the anti-tumorigenic and analgesic activity is due to the selective targeting of specific cathepsins that are known to facilitate osteolytic metastasis, bone invasion and bone matrix degradation.  We believe that these dat
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... 2014 2014 Deep Research Report ... research report on the Global Palmitic Acid industry. ... Acid, basic information, including definition, classification, application, industry ... analysis, etc. , For international and China ... market in China and other countries or ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
(Date:11/26/2014)... , Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, today ... the Piper Jaffray  26 th Annual Healthcare Conference on ... held at The New York Palace in New ... material information concerning the Company, its operations, strategies and prospects ...
Breaking Biology Technology:SoundConnect Appoints Director of Channel Development & Sales 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2
... OSAKA, Japan, Oct. 17 Affymax,Inc. (Nasdaq: ... 4502),today announced that they have been awarded the ... Society of the U.S. and Canada (LES),for their ... product candidate, Hematide(TM), for the treatment of,anemia. The ...
... to empower transplant patients ... and ... US,Inc. (Pink Sheets: ALPMF), a leader in the field of ... organization, announced a collaborative partnership to jointly,develop further materials for ...
... Oct. 17 /PRNewswire-FirstCall/ - Botaneco, a business unit ... has reached an,agreement with AVAC Ltd. for $2.4 ... as an independent business. The funding will be,paid ... the fourth,quarter of 2007, upon the formation of ...
Cached Biology Technology:Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 3Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Botaneco obtains $2.4 million in funding from AVAC 2Botaneco obtains $2.4 million in funding from AVAC 3
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
(Date:11/4/2014)... CORAL GABLES, Fla. (November 4, 2014) — Think about ... and ask: How do neighboring cells know that they ... cell and how do these tissues find the correct ... (UM) are answering these crucial questions. , In a ... tissues use to communicate with their surrounding neighbors, at ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2
... are declining worldwide, and their declines far exceed those ... species are listed as threatened according to the Red ... Nature (IUCN). Multiple factors threaten global amphibian diversity but ... are poorly known. A new study published in ...
... While previous studies have linked vitamin D deficiency to ... the Intermountain Medical Center Heart Institute shows that too ... a dangerous heart condition known as atrial fibrillation. ... the Intermountain Healthcare system, studied more than 132,000 patients ...
... NC The social lives of ants, wasps and bees ... societies colonies ruled by a queen and many workers ... ideas. Social insect society is divided into specialized castes ... members of a colony the workers forego their own ...
Cached Biology News:Predicting future threats for global amphibian biodiversity 2New study links excessive amounts of vitamin D to onset of atrial fibrillation 2New study links excessive amounts of vitamin D to onset of atrial fibrillation 3Communal living of the insect kind 2